Live Breaking News & Updates on Resources For The Center

Stay updated with breaking news from Resources for the center. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

RedHill Biopharma's Opaganib Inhibits COVID-19 Variants in Preclinical Study


-in
-class SK2 selective inhibitor targeting multiple indications with positive Phase 2 COVID-19 data and an ongoing Phase 2/3 program for COVID-19 and Phase 2 studies for prostate cancer and cholangiocarcinoma ongoing; (iii)
RHB-107 (upamostat), a serine protease inhibitor in a U.S. Phase 2/3 study as treatment for symptomatic COVID-19, and targeting multiple other cancer and inflammatory gastrointestinal diseases; (iv)
RHB-104, with positive results from a first Phase 3 study for Crohn s disease; (v)
RHB-102
(Bekinda
®), with positive results from a Phase 3 study for acute gastroenteritis and gastritis and positive results from a Phase 2 study for IBS-D; and (vi)
RHB-
106, an encapsulated bowel preparation. More information about the Company is available at www.redhillbio.com / https://twitter.com/RedHillBio.            ....

South Africa , United Kingdom , South African , William Severson , Delta Indian , Amber Fennell , Bryan Gibbs , Redhill Biopharma , Adi Frish , Opaganib Yeliva , Reza Fathi , Us National Institute Of Health , Redhill Biopharma Ltd , Resources For The Center , Exchange Commission , University Of Louisville Center , Company Annual Report On Form , Company Expanded Access Program , Corporate Business Development , University Of Louisville , Louisville Center , Predictive Medicine , Shared Resources , Orphan Drug , Hill Biopharma , Private Securities Litigation Reform Act ,